- Home
- LZ vs ADPT Comparison
LZ vs ADPT Comparison
Compare LZ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- ADPT
- Stock Information
- Founded
- LZ 2001
- ADPT 2009
- Country
- LZ United States
- ADPT United States
- Employees
- LZ N/A
- ADPT N/A
- Industry
- LZ EDP Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LZ Technology
- ADPT Health Care
- Exchange
- LZ Nasdaq
- ADPT Nasdaq
- Market Cap
- LZ 1.5B
- ADPT 1.8B
- IPO Year
- LZ 2021
- ADPT 2019
- Fundamental
- Price
- LZ $10.56
- ADPT $12.61
- Analyst Decision
- LZ Hold
- ADPT Strong Buy
- Analyst Count
- LZ 8
- ADPT 8
- Target Price
- LZ $10.83
- ADPT $12.38
- AVG Volume (30 Days)
- LZ 2.3M
- ADPT 1.8M
- Earning Date
- LZ 11-05-2025
- ADPT 11-06-2025
- Dividend Yield
- LZ N/A
- ADPT N/A
- EPS Growth
- LZ 47.91
- ADPT N/A
- EPS
- LZ 0.16
- ADPT N/A
- Revenue
- LZ $705,924,000.00
- ADPT $205,216,000.00
- Revenue This Year
- LZ $10.82
- ADPT $32.76
- Revenue Next Year
- LZ $7.18
- ADPT $15.81
- P/E Ratio
- LZ $65.12
- ADPT N/A
- Revenue Growth
- LZ 4.19
- ADPT 21.60
- 52 Week Low
- LZ $6.26
- ADPT $3.98
- 52 Week High
- LZ $11.93
- ADPT $13.68
- Technical
- Relative Strength Index (RSI)
- LZ 53.30
- ADPT 51.14
- Support Level
- LZ $10.13
- ADPT $12.34
- Resistance Level
- LZ $11.02
- ADPT $13.68
- Average True Range (ATR)
- LZ 0.33
- ADPT 0.56
- MACD
- LZ -0.12
- ADPT -0.08
- Stochastic Oscillator
- LZ 35.25
- ADPT 20.15
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).